BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stasi C, Silvestri C, Voller F, Cipriani F. The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine. J Infect Public Health 2016;9:389-95. [PMID: 26148849 DOI: 10.1016/j.jiph.2015.05.004] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Galun D, Mijac D, Filipovic A, Bogdanovic A, Zivanovic M, Masulovic D. Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. JPM 2022;12:149. [DOI: 10.3390/jpm12020149] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
2 Kasraian L, Imanieh MH, Tabrizi R, Shahriarirad R, Erfani A, Hosseini S. Prevalence of HBV and HCV Infections in Iranian Blood Donors; An Updated Systematic Review and Meta-Analysis. Middle East J Dig Dis 2021;13:237-52. [PMID: 36606217 DOI: 10.34172/mejdd.2021.231] [Reference Citation Analysis]
3 Zhao L, Yang Q, Liu J. Clinical Value Evaluation of microRNA-324-3p and Other Available Biomarkers in Patients With HBV Infection-Related Hepatocellular Carcinoma. Open Forum Infect Dis 2021;8:ofab108. [PMID: 34189151 DOI: 10.1093/ofid/ofab108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Battistella S, Lynch EN, Gambato M, Zanetto A, Pellone M, Shalaby S, Sciarrone SS, Ferrarese A, Germani G, Senzolo M, Burra P, Russo FP. Hepatocellular carcinoma risk in patients with HBV-related liver disease receiving antiviral therapy. Minerva Gastroenterol 2021;67. [DOI: 10.23736/s2724-5985.20.02791-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
5 Groopman JD. Changing Etiology and Epidemiology of Human Liver Cancer. Liver Cancer in the Middle East 2021. [DOI: 10.1007/978-3-030-78737-0_2] [Reference Citation Analysis]
6 Li X, Xu H, Gao P. Red Blood Cell Distribution Width-to-Platelet Ratio and Other Laboratory Indices Associated with Severity of Histological Hepatic Fibrosis in Patients with Autoimmune Hepatitis: A Retrospective Study at a Single Center. Med Sci Monit 2020;26:e927946. [PMID: 33180750 DOI: 10.12659/MSM.927946] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
7 Cheng H, Xu C, Zhang D, Zhang Z, Liu J, Lv X. Multiclass identification of hepatitis C based on serum Raman spectroscopy. Photodiagnosis Photodyn Ther 2020;30:101735. [PMID: 32171878 DOI: 10.1016/j.pdpdt.2020.101735] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Jiang M, Yan X, Song X, Yan Q, Zhao Y, Wang L, Gao P. Total bile acid to platelet ratio: A noninvasive index for predicting liver fibrosis in primary biliary cholangitis. Medicine (Baltimore) 2020;99:e20502. [PMID: 32481469 DOI: 10.1097/MD.0000000000020502] [Reference Citation Analysis]
9 Qi X, Wei C, Li Y, Wu Y, Xu H, Guo R, Jia Y, Li Z, Wei Z, Wang W, Jia J, Li Y, Wang A, Gao X. The characteristic of the synonymous codon usage and phylogenetic analysis of hepatitis B virus. Genes Genomics 2020;42:805-15. [PMID: 32462516 DOI: 10.1007/s13258-020-00932-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Hoter A, Rizk S, Naim HY. Heat Shock Protein 60 in Hepatocellular Carcinoma: Insights and Perspectives. Front Mol Biosci 2020;7:60. [PMID: 32351972 DOI: 10.3389/fmolb.2020.00060] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
11 Dagli O. Alkol ve uyuşturucu madde bağımlıları tedavi merkezinde hepatit ve HIV enfeksiyonlarının taranması. Pamukkale Medical Journal 2020. [DOI: 10.31362/patd.644886] [Reference Citation Analysis]
12 Gioula G, Sinakos E, Gigi E, Goulis I, Vasiliadis T, Minti F, Akriviadis E. 'Distribution of Hepatitis C Virus genotypes in northern Greece in the last decade: descriptive analysis and clinical correlations'. Glob Health Epidemiol Genom 2019;4:e5. [PMID: 31516719 DOI: 10.1017/gheg.2019.4] [Reference Citation Analysis]
13 Papadopoulos N, Vasileiadi S, Papavdi M, Sveroni E, Antonakaki P, Dellaporta E, Koutli E, Michalea S, Manolakopoulos S, Koskinas J, Deutsch M. Liver fibrosis staging with combination of APRI and FIB-4 scoring systems in chronic hepatitis C as an alternative to transient elastography. Ann Gastroenterol 2019;32:498-503. [PMID: 31474797 DOI: 10.20524/aog.2019.0406] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
14 Groopman JD. Environmental health in the biology century: Transitions from population to personalized prevention. Exp Biol Med (Maywood) 2019;244:728-33. [PMID: 30895818 DOI: 10.1177/1535370219837903] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Souliotis K, Saridi M, Banou K, Golna C, Paraskevis D, Hatzakis A, Smith A. Health and health needs of migrants in detention in Greece: shedding light to an unknown reality. Global Health 2019;15:4. [PMID: 30621722 DOI: 10.1186/s12992-018-0448-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Sghaier I, Brochot E, Loueslati BY, Almawi WY. Hepatitis C virus protein interaction network for HCV clearance and association of DAA to HCC occurrence via data mining approach: A systematic review and critical analysis. Rev Med Virol 2019;29:e2033. [PMID: 30614131 DOI: 10.1002/rmv.2033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
17 Salas-Coronas J, Cabezas-Fernández MT, Lozano-Serrano AB, Soriano-Pérez MJ, Vázquez-Villegas J, Cuenca-Gómez JÁ. Newly Arrived African Migrants to Spain: Epidemiology and Burden of Disease. Am J Trop Med Hyg 2018;98:319-25. [PMID: 29165212 DOI: 10.4269/ajtmh.17-0604] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
18 Viganò M, Loglio A, Lampertico P. Long-term Outcomes in Patients with HBV Treated with Antiviral Agents. Curr Hepatology Rep 2018;17:502-10. [DOI: 10.1007/s11901-018-0440-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 Cuenca-Gómez JÁ, Lozano-Serrano AB, Cabezas-Fernández MT, Soriano-Pérez MJ, Vázquez-Villegas J, Estévez-Escobar M, Cabeza-Barrera I, Salas-Coronas J. Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide treatment in real clinical practice. BMC Infect Dis 2018;18:568. [PMID: 30428845 DOI: 10.1186/s12879-018-3469-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
20 Rawla P, Sunkara T, Muralidharan P, Raj JP. Update in global trends and aetiology of hepatocellular carcinoma. Contemp Oncol (Pozn). 2018;22:141-150. [PMID: 30455585 DOI: 10.5114/wo.2018.78941] [Cited by in Crossref: 92] [Cited by in F6Publishing: 118] [Article Influence: 18.4] [Reference Citation Analysis]
21 Loglio A, Iavarone M, Grossi G, Viganò M, Rumi MG, Facchetti F, Lunghi G, Sangiovanni A, Colombo M, Lampertico P. Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B. Aliment Pharmacol Ther 2018;48:431-9. [PMID: 29920698 DOI: 10.1111/apt.14848] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
22 Vahedi F, Lee AJ, Collins SE, Chew MV, Lusty E, Chen B, Dubey A, Richards CD, Feld JJ, Russell RS, Mossman KL, Ashkar AA. IL-15 and IFN-γ signal through the ERK pathway to inhibit HCV replication, independent of type I IFN signaling. Cytokine 2019;124:154439. [PMID: 29908921 DOI: 10.1016/j.cyto.2018.06.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
23 Puchades Renau L, Berenguer M. Introduction to hepatitis C virus infection: Overview and history of hepatitis C virus therapies: Overview and history of hepatitis C therapies. Hemodialysis International 2018;22:S8-S21. [DOI: 10.1111/hdi.12647] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
24 Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 2018;68:526-49. [PMID: 28989095 DOI: 10.1016/j.jhep.2017.09.016] [Cited by in Crossref: 338] [Cited by in F6Publishing: 344] [Article Influence: 67.6] [Reference Citation Analysis]
25 Korda D, Lenard ZM, Gerlei Z, Jakab Z, Haboub-Sandil A, Wagner L, Varga M, Cseprekal O, Marton A, Horvathy D, Takacs S, Doros A, Mathe Z. Shear-wave elastography for the assessment of liver fibrosis in liver transplant recipients treated for hepatitis C virus recurrence. Eur J Gastroenterol Hepatol 2018;30:27-32. [PMID: 29049126 DOI: 10.1097/MEG.0000000000001003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
26 Ding L, Xiang C, Zhou G. Silica nanoparticles coated by poly(acrylic acid) brushes via host-guest interactions for detecting DNA sequence of Hepatitis B virus. Talanta 2018;181:65-72. [PMID: 29426543 DOI: 10.1016/j.talanta.2017.12.061] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
27 Keogh A, Şenkardeş S, Idle JR, Küçükgüzel ŞG, Beyoğlu D. A Novel Anti-Hepatitis C Virus and Antiproliferative Agent Alters Metabolic Networks in HepG2 and Hep3B Cells. Metabolites 2017;7:E23. [PMID: 28574427 DOI: 10.3390/metabo7020023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
28 Lam IF, Huang M, Chang MD, Yao PW, Chou YT, Ng SK, Tsai YL, Lin YC, Zhang YF, Yang XY, Lai YK. Identification of anti-HBV activities in Paeonia suffruticosa Andr. using GRP78 as a drug target on Herbochip®. Chin Med 2017;12:11. [PMID: 28450884 DOI: 10.1186/s13020-017-0132-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
29 Baumert TF, Jühling F, Ono A, Hoshida Y. Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. BMC Med 2017;15:52. [PMID: 28288626 DOI: 10.1186/s12916-017-0815-7] [Cited by in Crossref: 94] [Cited by in F6Publishing: 96] [Article Influence: 15.7] [Reference Citation Analysis]
30 Silvestri C, Bartolacci S, Pepe P, Monnini M, Voller F, Cipriani F, Stasi C. Attempt to calculate the prevalence and features of chronic hepatitis C infection in Tuscany using administrative data. World J Gastroenterol 2016; 22(44): 9829-9835 [PMID: 27956807 DOI: 10.3748/wjg.v22.i44.9829] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Domagalski K, Pawłowska M, Zaleśna A, Pilarczyk M, Rajewski P, Halota W, Tretyn A. Impact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus. World J Gastroenterol 2016; 22(41): 9186-9195 [PMID: 27895405 DOI: 10.3748/wjg.v22.i41.9186] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
32 Ospelnikova TP, Noseikina EM, Gaiderova LA, Ershov FI. THERAPEUTIC POTENTIAL OF ALPHA-INTERFERON PREPARATIONS DURING SOCIALLY-SIGNIFICANT HUMAN DISEASES OF VIRAL ETIOLOGY. Journal of microbiology, epidemiology and immunobiology 2016;93:109-121. [DOI: 10.36233/0372-9311-2016-5-109-121] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
33 Levin JM, Dabirshahsahebi S, Bauer M, Huckins E. Retrospective analysis of hepatitis C infected patients treated through an integrated care model. World J Gastroenterol 2016; 22(38): 8558-8567 [PMID: 27784968 DOI: 10.3748/wjg.v22.i38.8558] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
34 Vahidnia F, Stramer SL, Kessler D, Shaz B, Leparc G, Krysztof DE, Glynn SA, Custer B. Recent viral infection in US blood donors and health-related quality of life (HRQOL). Qual Life Res 2017;26:349-57. [DOI: 10.1007/s11136-016-1392-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
35 Pinchoff J, Tran OC, Chen L, Bornschlegel K, Drobnik A, Kersanske L, Fuld J. Impact of hepatitis B on mortality and specific causes of death in adults with and without HIV co-infection in NYC, 2000-2011. Epidemiol Infect 2016;144:3354-64. [PMID: 27510414 DOI: 10.1017/S0950268816001801] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
36 Lampertico P, Chan HL, Janssen HL, Strasser SI, Schindler R, Berg T. Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients. Aliment Pharmacol Ther 2016;44:16-34. [PMID: 27198929 DOI: 10.1111/apt.13659] [Cited by in Crossref: 71] [Cited by in F6Publishing: 57] [Article Influence: 10.1] [Reference Citation Analysis]
37 Cuenca-gómez J, Salas-coronas J, Soriano-pérez M, Vázquez-villegas J, Lozano-serrano A, Cabezas-fernández M. Viral hepatitis and immigration: A challenge for the healthcare system. Revista Clínica Española (English Edition) 2016;216:248-52. [DOI: 10.1016/j.rceng.2016.02.002] [Reference Citation Analysis]
38 Cuenca-Gómez JA, Salas-Coronas J, Soriano-Pérez MJ, Vázquez-Villegas J, Lozano-Serrano AB, Cabezas-Fernández MT. Viral hepatitis and immigration: A challenge for the healthcare system. Rev Clin Esp (Barc) 2016;216:248-52. [PMID: 26995326 DOI: 10.1016/j.rce.2016.02.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
39 Groopman JD. Environmental Carcinogens and Risk for Human Liver Cancer. Hepatocellular Carcinoma 2016. [DOI: 10.1007/978-3-319-34214-6_2] [Reference Citation Analysis]